Netupitant-Palonosetron FDC Market Report 2026

The netupitant-palonosetron fdc market size has grown strongly in recent years. It will grow from $384.5 billion in 2025 to $422.35 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to limited availability of netupitant and palonosetron formulations, reliance on conventional antiemetic therapies, growing chemotherapy patient population, increasing hospital and oncology clinic setups, rising awareness of cinv management.

The netupitant-palonosetron fdc market size is expected to see strong growth in the next few years. It will grow to $608.99 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to development of novel fdc formulations, expansion of oral and sublingual drug delivery, rising investment in oncology treatments, adoption of personalized antiemetic regimens, increasing penetration through online and specialty pharmacies. Major trends in the forecast period include rising adoption of fixed-dose combination (fdc) therapies, increasing use of oral and sublingual anti-nausea treatments, expansion of chemotherapy and oncology care facilities, growing awareness about postoperative nausea and vomiting management, enhanced focus on patient-centric drug delivery systems.

The rising prevalence of cancer is anticipated to drive the growth of the netupitant-palonosetron fixed-dose combination (FDC) market in the coming years. Cancer encompasses a group of diseases marked by the uncontrolled growth and spread of abnormal cells throughout the body. The increasing incidence of cancer is largely attributed to lifestyle factors such as unhealthy diets, tobacco use, physical inactivity, and excessive alcohol consumption. The netupitant-palonosetron fixed-dose combination (FDC) supports cancer care by combining two effective antiemetic agents that prevent both acute and delayed chemotherapy-induced nausea and vomiting, thereby improving patient comfort and adherence to treatment and contributing to better overall care outcomes. For instance, in February 2025, according to Cancer Australia, an Australia-based government agency, 4,641 new pancreatic cancer cases were reported in 2024, including 2,414 cases in males and 2,227 in females, representing an increase from 3,968 cases in 2023. Therefore, the increasing prevalence of cancer is fueling the growth of the netupitant-palonosetron fixed-dose combination (FDC) market.

Major companies operating in the netupitant-palonosetron fixed-dose combination (FDC) market are concentrating on the development of advanced formulation products, such as ready-to-use intravenous formulations, to improve patient convenience and treatment effectiveness. Ready-to-use intravenous formulations are pre-prepared, sterile drug solutions that do not require dilution or mixing, thereby simplifying administration and reducing preparation errors when using netupitant-palonosetron FDC therapies. For example, in June 2024, Helsinn Group, a Switzerland-based pharmaceutical company, introduced AKYNZEO (fosnetupitant/palonosetron) injection, a ready-to-use vial launched in the United States. This formulation is intended to streamline preparation and administration for healthcare professionals, enhancing convenience in clinical settings. The injection requires no reconstitution or dilution and can be administered directly from the vial using an integrated hanging strap.

In January 2025, Helsinn Healthcare SA (Helsinn Group), a Switzerland-based pharmaceutical company, entered into a partnership with ESTEVE, S.A. to renew their distribution and licensing agreement for AKYNZEO (netupitant-palonosetron) and ALOXI (palonosetron) in Germany. Through this collaboration, Helsinn and ESTEVE aim to maintain patient access to essential supportive care treatments for chemotherapy-induced nausea and vomiting (CINV), reinforcing their long-standing partnership in oncology supportive care. ESTEVE S.A. is a Spain-based specialty pharmaceutical company focused on highly specialized therapies.

Major companies operating in the netupitant-palonosetron fdc market are Taiho Pharmaceutical Co. Ltd., Aurobindo Pharma Limited, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd, Dr. Reddy’s Laboratories Ltd., Zhejiang Tiantai Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Limited, Helsinn Group, Heron Therapeutics Inc., Metrochem API Private Limited, Mundipharma Pty Ltd, Guangzhou Tosun Pharmaceutical Co. Ltd., Tesaro Inc., Accord Healthcare Ltd., Century Pharmaceuticals Ltd., Specialised Therapeutics Australia Pty Ltd., Aark Pharmaceuticals Ltd., Chemicea Pharmaceuticals Pvt. Ltd., Teva Pharmaceutical Industries Ltd.

North America was the largest region in the netupitant-palonosetron fixed dose combination (FDC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the netupitant-palonosetron fdc market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the netupitant-palonosetron fdc market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the netupitant-palonosetron FDC market by increasing the cost of imported active pharmaceutical ingredients (APIs) and excipients used in oral, intravenous, and sublingual formulations. Segments like intravenous FDCs and injectable palonosetron are particularly affected, with regions such as Asia-Pacific and Europe facing notable import duties. This has led to higher production costs and adjustments in distribution pricing. On the positive side, tariffs have encouraged local API manufacturing, boosted domestic formulation capabilities, and incentivized innovation in cost-effective FDC production.

The netupitant-palonosetron fdc market research report is one of a series of new reports that provides netupitant-palonosetron fdc market statistics, including netupitant-palonosetron fdc industry global market size, regional shares, competitors with a netupitant-palonosetron fdc market share, detailed netupitant-palonosetron fdc market segments, market trends and opportunities, and any further data you may need to thrive in the netupitant-palonosetron fdc industry. This netupitant-palonosetron fdc market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The netupitant-palonosetron fixed-dose combination (FDC) is a pharmaceutical formulation that integrates two active agents - netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin (5-HT3) receptor antagonist - into a single dosage form. This combination is mainly used for the prevention of both acute and delayed nausea and vomiting associated with chemotherapy. Netupitant acts by inhibiting the effects of substance P at NK1 receptors in the brain, while palonosetron blocks serotonin activity at 5-HT3 receptors, which are critical pathways involved in chemotherapy-induced nausea and vomiting (CINV).

The key product types of the netupitant-palonosetron fixed-dose combination (FDC) include netupitant, palonosetron, and the fixed-dose combination itself. Netupitant is a drug used to prevent chemotherapy-related nausea and vomiting by blocking substance P/neurokinin-1 (NK1) receptors. It is administered via oral, intravenous (IV), and sublingual routes and is used in the management of chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), and general nausea. Distribution channels include hospitals, retail pharmacies, online pharmacies, and specialty clinics.

The netupitant-palonosetron fixed dose combination (FDC) market consists of sales of oral capsules, injectable formulations, premixed infusion bags, combination therapy kits, and generic versions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.